
# Transient Elastography

**Transient Elastography (TE) has been listed in the guidelines for prevention and treatment of liver diseases and expert consensus on clinical application in many countries and regions worldwide.**







# Dynamic Wideband Fibrosis Scanning Probe

- Applicable to different body sizes, highly successful detection rate
- Controlled probe pressure ensures high detection accuracy
- Optimized scientific algorithms provide fast and quantitative results



# Clinical Advantages of FibroTouch®


| | |
|---|---|
| **Non-Invasive** | **No need for blood collection, repeatable, thus good for follow-up of patients with liver fibrosis and steatosis and evaluation of treatment effect** |
| **Rapid** | **The examination only takes a few minutes, and the measurement results can be obtained quickly** |
| **Accurate** | **The liver tissue sample volume is 100 times larger than a liver biopsy sample, which can fully reflect the liver condition. The test results have high consistency with liver biopsy results** |
| **Quantitative** | **Simultaneous detection of liver fibrosis and steatosis quantitatively, easily track and compare multiple measured results for the same patient** |

# Who are applicable for FibroTouch® examination?

- People who are at high risk of liver injury due to unhealthy life styles, such as alcoholism, smoking, staying up late at night, irregular diet, anger, depression, etc.
- People who are in sub-health state, such as fatty liver, obesity,high blood pressure, hyperlipidemia, hyperglycemia, diabetes, coronary disease, etc.
- People with chronic liver diseases, such as different types of viral hepatitis, biliary tract disease, long-term medication, etc.
- People who need regular liver health management for prevention and assessment



# FibroTouch® has high consistency with liver biopsy, which is superior to APRI and FIB-4

| | |
|---|---|
| Literature Title | **Clinical study on transient elastography and multiparameter models for diagnosis of hepatic fibrosis in patients with chronic liver disease**. |
| Objectives | To evaluate the clinical application of transient elastography (FibroTouch®) in the diagnosis of liver fibrosis in patients with chronic liver diseases and to identify whether FibroTouch® is a more accurate and safe method in diagnosis of liver fibrosis. |
| Methods | A total of 190 patients with chronic liver disease were enrolled for study<br>Patients were performed liver biopsy and underwent liver stiffness measurement(LSM) using FibroTouch®; Serum alanine aminotransferase (ALT),aspartate aminotransferase (AST) and total bilirubin (TBIL) were tested by enzymic method with automatic biochemistry analyzer; Platelet count (PLT) was detected by automatic blood cell analyzer; AST-to-PLT ratio index (APRI) and fibrosis index based on the 4 factor (FIB-4) were calculated. The diagnostic values of FibroTouch®, APRI and FIB-4 for liver fibrosis degree were calculated and compared by receiver operating characteristic (ROC) curves. The related factors of LSM were analyzed by Spearman analysis. |
| Charts | <br>Note<br>A:ROC curve of liver pathological staging of S≥2<br>B:ROC curve of liver pathological staging of S≥3<br>C:ROC curve of liver pathological staging of S=4<br>ROC curves of liver pathological fibrosis staging evaluated by FibroTouch®, APRI and FIB-4 index |
| Conclusions | 1.There was significant correlation between LSM and histological fibrosis, FibroTouch® can accurately assess the degree of hepatic fibrosis and it's a good alternative to liver biopsy.<br>2.FibroTouch® is a convenient and reliable approach for diagnosis of liver fibrosis in patients with chronic liver disease. The sensitivity and specificity of FibroTouch® in diagnosis of hepatic fibrosis is superior to APRI and FIB-4. |

HISKY

WWW.FIBROTOUCH.COM

EXPORT@FIBROTOUCH.COM

CE 0123


Wuxi Hisky Medical Technologies Co.,Ltd. All rights reserved. Specifications subject to change without prior notice.

FIBROTOUCH®

# Innovative Solution for Liver Diagnosis

**Non-invasive Assessment of Liver Fibrosis and Steatosis**

Early Screening | Early Detection | Regular Follow-up



HISKY